Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | IL6 | P05231 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | GALR1 | P47211 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23595847 | 1.00 | HDAC4 (0.51) | HDAC4PDE7AHSD11B1GRIN1GRIN2A | |
| SCHEMBL21452547 | 1.00 | HDAC4 (0.51) | HDAC4PDE7AHSD11B1GRIN1GRIN2A | |
| SCHEMBL21452476 | 0.87 | PDE7A (0.42) | HDAC4PDE7AHSD11B1GRIN1GRIN2A | |
| SCHEMBL21452548 | 0.82 | HDAC4 (0.48) | HDAC4PDE7AHSD11B1KDM1AGALR1 | |
| SCHEMBL21452500 | 0.81 | KDM1A (0.35) | HDAC4KDM1A | |
| SCHEMBL27173461 | 0.80 | HDAC4 (0.47) | HDAC4PDE7AHSD11B1GRIN1GRIN2A | |
| SCHEMBL22731062 | 0.79 | HDAC4 (0.51) | HDAC4PDE7AHSD11B1GRIN1GRIN2A | |
| SCHEMBL21452481 | 0.78 | HDAC4 (0.37) | HDAC4PDE7AGRIN1GRIN2ASLC6A4 | |
| SCHEMBL23595808 | 0.78 | GRIN1 (0.42) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B | |
| SCHEMBL23595770 | 0.78 | GRIN1 (0.42) | GRIN1GRIN2ASLC6A4GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS INC (US) | 2022-12-29 | — | — | US | disclosed |
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | GILGAMESH PHARMACEUTICALS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2021134086-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344510-B2 | Arylcyclohexylamine derivatives and their use in the treatment of psychiatric disorders | HTR2C, PNMT, HTR2A | HDAC4 297/4885PDE7A 2524/4885HSD11B1 1048/4885 |
| US-20220409555-A1 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | HTR2C, PNMT, HTR2A | HDAC4 307/4885PDE7A 2384/4885HSD11B1 1388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.